Hydromorphon-Hcl Abz (Hydromorphone Hydrochloride)

Hydromorphone binds tightly to µ‑opioid receptors in the brain and spinal cord, activating them to inhibit the release of excitatory neurotransmitters. This reduces neuronal firing and blocks transmission of pain signals, producing strong analgesia and a degree of sedation.

The appropriate dose of hydromorphone is individualized. A qualified prescriber determines the strength, frequency, and duration based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition.

Safety data for hydromorphone in pregnancy and lactation are limited. Because opioids can cross the placenta and enter breast milk, the drug is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydromorphone is roughly five to seven times more potent than morphine on a milligram‑for‑milligram basis. Both act on µ‑opioid receptors, but hydromorphone often provides faster onset and may be preferred when stronger analgesia is needed with smaller tablet sizes.

Store the product at room temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture, direct sunlight and extreme temperatures to maintain potency and stability.

Hydromorphon-Hcl Abz is intended for oral use. The tablet should be swallowed whole with a full glass of water and not chewed, crushed, or broken unless specifically instructed by a healthcare professional.

The most critical risks include respiratory depression, severe hypotension, profound sedation, dependence or addiction, and rare events such as serotonin syndrome or anaphylaxis. Prompt medical attention is required if any of these occur.

Hydromorphone is contraindicated in patients with known hypersensitivity to hydromorphone or other opioids, those with significant respiratory depression, acute or severe bronchial asthma, and in individuals taking MAO inhibitors within the past 14 days.